PharmaShots | Incisive News in 3 Shots

Subscribe Now

Keynote-426 Study

Merck Reports Results of Keytruda (pembrolizumab) + Inlyta (axitinib) in P-III KEYNOTE-426 Study in Patients with 1L Advanced Renal Cell Carcinoma (RCC)

Merck Reports Results of Keytruda (pembrolizumab) + Inlyta (axitinib) in P-III KEYNOTE-426 Study in Patients with 1L Advanced Rena...

February 18, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us